Digestive Disease Week

Digestive Disease Week

May 16, 2015
2 min read
Save

Statin use offers protection from new onset IBD

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

WASHINGTON — No matter the statin used, these medications were associated with a decreased risk of new-onset inflammatory bowel disease with increased protection in older patients, according to data presented at Digestive Disease Week 2015.

“Exposure to statins may decrease risk of new onset IBD by about 40%,” Ryan C. Ungaro, MD, of Icahn School of Medicine at Mount Sinai, in New York City, said in his presentation. “The risk decreased with all specific statins.”

In this retrospective study, Ungaro and colleagues looked a health claims database and included 87,579 cases of IBD matched with 189,526 controls.

Statins as a class showed a protective effect for new onset IBD (OR = 0.593; 95% CI, 0.576-0.61), Crohn's disease (OR = 0.555; 95% CI, 0.531-0.579) and ulcerative colitis (OR = 0.625; 95% CI, 0.6-0.65).

All studied statins — simvastatin (Zocor, Merck), atorvastatin (Lipitor, Pfizer), rosuvastatin (Crestor, AstraZeneca), pravastatin and lovastatin — conferred similar benefits to the patients in reference to new onset of disease. Intensity of therapy gave subsequently more protection for low (OR = 0.57; 95% CI, 0.527-0.617), moderate (OR = 0.595; 95% CI, 0.576-0.615) and high (OR = 0.593; 95% CI, 0.56-0.628) intensity therapy, though the difference was not significant.

“Different intensities of therapy did not significantly differ in the magnitude of protective effect,” Ungaro told Healio Gastroenterology.

Additionally, patients older than 60 years showed increased protection against IBD (OR = 0.559; 95% CI, 0.539-0.58), Crohn’s (OR = 0.505; 95% CI, 0.475-0.536) and ulcerative colitis (OR = 0.602; 95% CI, 0.572-0.633) while those in the 18- to 30-year age group showed less impact (IBD OR = 0.897; 95% CI, 0.637-1.262).

When adjusted for covariates such as lipid metabolism disorders, cardiovascular disease and other medications, the protective factor for IBD was maintained (OR = 0.604; 95% CI, 0.586-0.623).

“This association appears stronger in older patient populations,” Ungaro said. “The effect remains unchanged after adjusting the model for covariates.” — Katrina Altersitz

Reference:

Ungaro RC, et al. Abstract 7. Presented at: Digestive Disease Week, May 16-19, 2015; Washington, D.C. 

Disclosure: Ungaro reports no relevant financial disclosures. Please see the DDW faculty disclosure index for all other researchers’ relevant financial disclosures.

Editor's note: This article was updated on May 27, 2015, with clarifications from the presenter.